These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 26961122)
1. Inverse agonism: the classic concept of GPCRs revisited [Review]. Sato J; Makita N; Iiri T Endocr J; 2016 Jun; 63(6):507-14. PubMed ID: 26961122 [TBL] [Abstract][Full Text] [Related]
2. Inverse agonists: tools to reveal ligand-specific conformations of G protein-coupled receptors. Prather PL Sci STKE; 2004 Jan; 2004(215):pe1. PubMed ID: 14722344 [TBL] [Abstract][Full Text] [Related]
3. Current topics in angiotensin II type 1 receptor research: Focus on inverse agonism, receptor dimerization and biased agonism. Takezako T; Unal H; Karnik SS; Node K Pharmacol Res; 2017 Sep; 123():40-50. PubMed ID: 28648738 [TBL] [Abstract][Full Text] [Related]
4. The nature of efficacy at G protein-coupled receptors. Zhao P; Furness SGB Biochem Pharmacol; 2019 Dec; 170():113647. PubMed ID: 31585071 [TBL] [Abstract][Full Text] [Related]
5. Molecular basis of inverse agonism in a G protein-coupled receptor. Vilardaga JP; Steinmeyer R; Harms GS; Lohse MJ Nat Chem Biol; 2005 Jun; 1(1):25-8. PubMed ID: 16407989 [TBL] [Abstract][Full Text] [Related]
6. Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Seifert R; Wenzel-Seifert K Naunyn Schmiedebergs Arch Pharmacol; 2002 Nov; 366(5):381-416. PubMed ID: 12382069 [TBL] [Abstract][Full Text] [Related]
7. Biased Agonism/Antagonism of Cardiovascular GPCRs for Heart Failure Therapy. Desimine VL; McCrink KA; Parker BM; Wertz SL; Maning J; Lymperopoulos A Int Rev Cell Mol Biol; 2018; 339():41-61. PubMed ID: 29776604 [TBL] [Abstract][Full Text] [Related]
8. Assessment of inverse agonism for the angiotensin II type 1 receptor. Akazawa H; Yasuda N; Miura S; Komuro I Methods Enzymol; 2010; 485():25-35. PubMed ID: 21050909 [TBL] [Abstract][Full Text] [Related]
9. Structure-Function Basis of Attenuated Inverse Agonism of Angiotensin II Type 1 Receptor Blockers for Active-State Angiotensin II Type 1 Receptor. Takezako T; Unal H; Karnik SS; Node K Mol Pharmacol; 2015 Sep; 88(3):488-501. PubMed ID: 26121982 [TBL] [Abstract][Full Text] [Related]
10. Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Kenakin T Mol Pharmacol; 2004 Jan; 65(1):2-11. PubMed ID: 14722230 [TBL] [Abstract][Full Text] [Related]
11. Structural requirements for inverse agonism and neutral antagonism of indole-, benzimidazole-, and thienopyrrole-derived histamine H4 receptor ligands. Schneider EH; Strasser A; Thurmond RL; Seifert R J Pharmacol Exp Ther; 2010 Aug; 334(2):513-21. PubMed ID: 20484153 [TBL] [Abstract][Full Text] [Related]
12. Functional selectivity through protean and biased agonism: who steers the ship? Kenakin T Mol Pharmacol; 2007 Dec; 72(6):1393-401. PubMed ID: 17901198 [TBL] [Abstract][Full Text] [Related]
13. Constitutive activity and inverse agonists of G protein-coupled receptors: a current perspective. Milligan G Mol Pharmacol; 2003 Dec; 64(6):1271-6. PubMed ID: 14645655 [TBL] [Abstract][Full Text] [Related]
14. Assessing receptor affinity for inverse agonists: Schild and Cheng-Prusoff methods revisited. Giraldo J; Serra J; Roche D; Rovira X Curr Drug Targets; 2007 Jan; 8(1):197-202. PubMed ID: 17266542 [TBL] [Abstract][Full Text] [Related]
15. Constitutive activities and inverse agonism in dopamine receptors. Zhang B; Albaker A; Plouffe B; Lefebvre C; Tiberi M Adv Pharmacol; 2014; 70():175-214. PubMed ID: 24931197 [TBL] [Abstract][Full Text] [Related]
20. Constitutive activation of G protein-coupled receptors and diseases: insights into mechanisms of activation and therapeutics. Tao YX Pharmacol Ther; 2008 Nov; 120(2):129-48. PubMed ID: 18768149 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]